Anti-ageing drug tested for the first time on humans: Injected into the pupil of a patient suffering from glaucoma

The first human trial of one of the most important goals of medical science, 'reverse-aging', has begun. This is the first time that an injection that reverses the effect of age has been given to a human being. Boston-based biotech startup Life Biosciences said its first patient has been injected with cellular reprogramming. Under the trial, the injection was injected into one of the pupils of a patient suffering from glaucoma (black cataract). The main objective of this trial is to rejuvenate and activate cells that have become weakened due to ageing. For the next 6 months, scientists will monitor its impact and side effects. Successful tests have already been conducted on mice and monkeys. Now doctors and scientists will closely monitor the patient for the next several months to ensure that the technique is completely safe for the human body. In this therapy, a single gene therapy is first injected into the patient's eye. This will be followed by a special course of antibiotics for a few weeks. The antibiotic will go inside the body and act as an 'on switch' for those three therapeutic genes, which begin to reprogram the cells. Earlier, he had successfully restored his vision in tests conducted on mice and monkeys. The human eye has been chosen for this therapy because the eye is separate and protected from the rest of the body. This also makes it easier to monitor side effects. Jerry McLaughlin, CEO of Life Biosciences, said this is a potentially big and transformative moment not only for his company or aging biology, but for medical science as a whole. If this clinical trial is successful, it could usher in a new era in aging therapy. The goal is to rejuvenate and activate cells throughout the body, so that the way DNA works and expresses itself can improve as we age. Investments by billionaires and pharma companies Many big investors, including Amazon founder Jeff Bezos and OpenAI's Sam Altman, have invested in this technique. Pharmaceutical companies like Eli Lilly and Merck are also increasing investment in this idea. Before the trials on humans, this research was limited to mice and monkeys, which has now reached humans.